SCHEMBL15519989

SCHEMBL15519989

CCOC(=O)c1cc([Si](C)(C)C)nn1-c1cccc(CO)c1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
POLB P06746 2/20 0.45
LMNA P02545 1/20 0.44
SCN9A Q15858 1/20 0.44
SMN1; SMN2 Q16637 5/20 0.41
KMT2A Q03164 2/20 0.41
PDE4D Q08499 2/20 0.40
PDE4B Q07343 1/20 0.40
HTT P42858 1/20 0.40
TDP1 Q9NUW8 1/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 1/20 0.39
FAAH O00519 1/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15517367 0.90 ALDH1A1 (0.44) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL20028223 0.87 KMT2A (0.53) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15517248 0.87 ALDH1A1 (0.42) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL19750003 0.86 SCN9A (0.46) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15518413 0.85 ALDH1A1 (0.50) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15519630 0.83 GRN (0.50) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL20015969 0.81 SCN9A (0.42) ALDH1A1POLBLMNASCN9ASMN1; SMN2
SCHEMBL15519124 0.79 ALDH1A1 (0.52) ALDH1A1POLBLMNASMN1; SMN2KMT2A
SCHEMBL15517521 0.78 ALDH1A1 (0.51) ALDH1A1POLBLMNASMN1; SMN2KMT2A
SCHEMBL20027770 0.76 KMT2A (0.52) ALDH1A1POLBLMNASCN9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9796742-B2 Kinase inhibitors RESPIVERT LIMITED (GB) 2017-10-24 US disclosed
EP-2890460-B1 KINASE INHIBITORS RESPIVERT LTD (GB) 2017-02-22 EP disclosed
US-20160340375-A1 KINASE INHIBITORS OXULAR ACQUISITIONS LIMITED (GB) 2016-11-24 US disclosed
US-20150210722-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2015-07-30 US disclosed
EP-2890460-A1 KINASE INHIBITORS Respivert Limited (GB) 2015-07-08 EP disclosed
WO-2014033446-A1 KINASE INHIBITORS RESPIVERT LIMITED (GB) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150210722-A1 KINASE INHIBITORS SYK, SRC, LYN ALDH1A1 2702/4885POLB 3918/4885LMNA 2738/4885
US-20160340375-A1 KINASE INHIBITORS SYK, LYN, BTK ALDH1A1 2639/4885POLB 3978/4885LMNA 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.